Novartis and AveXis shares saw big gains in Monday trading after it was announced that the Swiss drugmaker would be buying the gene therapy company for $8.7 billion in cash. Novartis announced that it would be paying $218 a share for AveXis, a number that represents a 72% premium compared to the stock’s 30-day volume … Continue reading “Novartis Just Made an $8.7 Billion Dollar Bet on this Gene Therapy Company”
Biotech & Pharma
Biotech & Pharma
Incyte Shares Fall after Combo Drug with Merck Failed in Study
Shares of Incyte fell 20% on Friday after a combo therapy with drug giant Merck…
April 7, 2018
Biotech & Pharma
Celgene Loses its President and COO
This week biotech giant Celgene Corporation announced that it's president and chief operating officer, Scott…
April 4, 2018
Biotech & Pharma
Alkermes Shares Collapse as FDA Refuses to Review its MLajor Depressive Disorder Drug
Shares of biotech stock Alkermes were falling into the red on Monday after the Food…
April 2, 2018
Biotech & Pharma
GlaxoSmithKline to Buy Novartis AG’s Stake in Consumer-Health Joint Venture for $13B
One of the biggest headlines in the healthcare arena on Tuesday was that GlaxoSmithKline Plc,…
March 27, 2018
Biotech & Pharma
Japan Just Approved a Drug That Promises to Kill Flu in Only 24 Hours
It has been a very scary flu season this year as some people, young and…
February 23, 2018
Biotech & Pharma
Allergan Smashes in its Earnings Report
Biopharma company Allergan has reported stellar fourth-quarter adjusted earnings. The company also revealed that the…
February 6, 2018
Biotech & Pharma
Warren Buffet, Jeff Bezos, and Jamie Dimon are Shaking up the Healthcare Industry
One of the biggest headlines on Tuesday was the announcement that Amazon's CEO Jeff Bezos,…
January 30, 2018
Biotech & Pharma
Sanofi is Closing a Deal to Buy This U.S. Drug Maker
Reported on Monday by the Wall Street Journal which cited people who are close to…
January 22, 2018
Biotech & PharmaFeatured
Gilead Sciences Will Collaborate with Pfizer Over This Therapy
It was announced this week that Kite Pharma Inc., a subsidiary of Gilead Sciences, has…
January 20, 2018
Biotech & Pharma
Spark Therapeutics Can Cure Rare Blindness For $850,000
Spark Therapeutics' Luxturna is a gene therapy that treats a rare inherited retinal disease that…
January 3, 2018
Biotech & Pharma
Trevena Soars on FDA News Over Opioid Replacement Pain Killer
Trevena shares were on fire in after hours trading on Tuesday after the biotech company…
January 2, 2018
Biotech & Pharma
The FDA Has Approved Spark Therapeutics’ Luxturna Therapy
In what is the first in the field of gene therapy, Spark Therapeutics' Luxturna has…
December 19, 2017
Biotech & Pharma
Sage Therapeutics Shares Skyrocket on Positive Depression Drug Trial Results
Shares of Sage Therapeutics were climbing fast on Thursday after the company announced positive mid-stage…
December 7, 2017